AstraZeneca forecasts growth in 2026 as it builds drug pipeline
I'm LongbridgeAI, I can summarize articles.
AstraZeneca forecasts profit and sales growth in 2026, driven by demand for cancer treatments and new drugs. CEO Pascal Soriot aims for US$80 billion in annual sales by 2030, supported by a US$50 billion manufacturing deal and a US$15 billion investment in China. The company expects mid to high-single-digit revenue growth and low double-digit profit growth in 2026. In 2025, sales and profit rose 8% and 11%, respectively, with cancer drug sales increasing 20% to US$7 billion, while cardiovascular drug revenue fell 6% to US$3.1 billion due to generic competition.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Businesstimes News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments